Press release
Tay-Sachs Disease Pipeline 2025: Groundbreaking Clinical Advancements by 4+ Global Leaders - DelveInsight | Featuring Sanofi Genzyme, IntraBio
Tay-Sachs Disease Pipeline 2025, DelveInsight
DelveInsight's "Tay-Sachs Disease Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Tay-Sachs Disease Therapeutics Market and the breakthroughs shaping its future trajectory.
Explore the Cutting-Edge Landscape of Tay-Sachs Disease Drug Development @ https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Tay-Sachs Disease Pipeline Report
DelveInsight's Tay-Sachs Disease pipeline report depicts a robust space with 4+ active players working to develop 5+ pipeline therapies for Tay-Sachs Disease treatment.
Developed by Axovant Gene Therapies, this gene therapy utilizes adeno-associated viral vectors to deliver functional HEXA and HEXB genes to the central nervous system. In 2020, the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for AXO-AAV-GM2, allowing the initiation of a registrational study for Tay-Sachs and Sandhoff diseases. The therapy has received Orphan Drug and Rare Pediatric Disease Designations from the FDA .
Key Tay-Sachs Disease companies such as Sanofi Genzyme, IntraBio, and others are evaluating new drugs for Tay-Sachs Disease to improve the treatment landscape.
Promising Tay-Sachs Disease pipeline therapies in various stages of development include Venglustat, IB1001, and others.
Tay-Sachs Disease Overview:
Tay-Sachs disease is a severe inherited disorder that primarily impacts the nervous system, caused by a deficiency in the enzyme beta-hexosaminidase A due to mutations in the *HEXA* gene on chromosome 15. This enzyme plays a critical role in breaking down GM2 ganglioside, a type of lipid, within lysosomes. Without adequate levels of beta-hexosaminidase A, GM2 builds up in nerve cells, leading to progressive neurological damage. Tay-Sachs is inherited in an autosomal recessive manner, meaning a child must receive a faulty gene from both parents to develop the disease. Carriers-those with only one mutated gene-typically show no symptoms. Due to its impact on lysosomal function and GM2 accumulation, Tay-Sachs is classified as both a lysosomal storage disorder and a GM2-gangliosidosis.
The disease is categorized into three main types based on the age of symptom onset: infantile, juvenile, and late-onset. The infantile form is the most severe, with symptoms emerging around six months of age. These include loss of motor skills, heightened startle reflex, seizures, hearing and vision loss, and a characteristic "cherry-red" spot on the retina. Neurological deterioration occurs rapidly, and affected children usually do not survive past early childhood. Juvenile Tay-Sachs appears later, during early childhood or adolescence, and is marked by issues with coordination, speech, and cognitive function. Though slower in progression than the infantile form, it remains a serious condition and is often fatal by early adulthood.
Download the Tay-Sachs Disease sample report to know in detail about the Tay-Sachs Disease treatment market @ https://www.delveinsight.com/sample-request/tay-sachs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Tay-Sachs Disease Pipeline Analysis
The Tay-Sachs Disease pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Tay-Sachs Disease Market.
Categorizes Tay-Sachs Disease therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Tay-Sachs Disease drugs under development based on:
Stage of development
Tay-Sachs Disease Route of administration
Target receptor
Monotherapy vs. combination therapy
Tay-Sachs Disease Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Tay-Sachs Disease Licensing agreements
Funding and investment activities supporting future Tay-Sachs Disease market advancement.
Unlock key insights into emerging Tay-Sachs Disease therapies and market strategies here: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Tay-Sachs Disease Emerging Drugs
Venglustat: Sanofi Genzyme
Venglustat is an experimental oral therapy designed to slow disease progression by targeting and reducing the buildup of glycosphingolipids (GSLs). It is currently in clinical trials and has not yet been approved by any regulatory agency. The U.S. FDA has granted Venglustat Fast Track designation for Gaucher disease type 3, Fabry disease, and GM2 gangliosidosis. Additionally, it has received Orphan Drug Designation in both the U.S. and Europe for treating GM2 gangliosidosis. Venglustat is currently in Phase III clinical development for Tay-Sachs disease.
IB1001: IntraBio
IB1001 is an innovative oral therapy developed by IntraBio, a U.S.-based biopharmaceutical company specializing in treatments for rare and common neurological disorders. The drug is a modified amino acid (N-acetyl-L-leucine) that utilizes a unique transport system to reach target tissues, including crossing the blood-brain barrier. This action helps restore normal lysosomal and mitochondrial function, which in turn reduces neuroinflammation and stabilizes neuronal membrane potential and intracellular ion balance through calcium channels. IB1001 is currently in Phase II clinical trials for the treatment of Tay-Sachs disease.
Tay-Sachs Disease Pipeline Therapeutic Assessment
Tay-Sachs Disease Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Tay-Sachs Disease By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Tay-Sachs Disease Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Tay-Sachs Disease Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Tay-Sachs Disease therapies and key Tay-Sachs Disease companies: https://www.delveinsight.com/sample-request/tay-sachs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Tay-Sachs Disease Current Treatment Patterns
4. Tay-Sachs Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Tay-Sachs Disease Late-Stage Products (Phase-III)
7. Tay-Sachs Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Tay-Sachs Disease Discontinued Products
13. Tay-Sachs Disease Product Profiles
14. Tay-Sachs Disease Key Companies
15. Tay-Sachs Disease Key Products
16. Dormant and Discontinued Products
17. Tay-Sachs Disease Unmet Needs
18. Tay-Sachs Disease Future Perspectives
19. Tay-Sachs Disease Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Tay-Sachs Disease pipeline reports offerings: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tay-Sachs Disease Pipeline 2025: Groundbreaking Clinical Advancements by 4+ Global Leaders - DelveInsight | Featuring Sanofi Genzyme, IntraBio here
News-ID: 4026257 • Views: …
More Releases from DelveInsight Business Research LLP
Idiopathic Membranous Nephropathy Treatment Market Size Expected to Grow Major G …
DelveInsight's "Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Complicated Urinary Tract Infection (cUTI), historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection (cUTI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore Idiopathic Membranous Nephropathy Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
…
Age-related Vision Dysfunction Treatment Market Size Expected to Grow Major Grow …
DelveInsight's "Age-related Vision Dysfunction Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock key insights into the Age-related Vision Dysfunction Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and…
Warm Autoimmune Hemolytic Anemia Market Size Expected to Grow Major Growth by 20 …
DelveInsight has released a new report, "Warm Autoimmune Hemolytic Anemia Market Insights, Epidemiology, and Market Forecast-2034", providing comprehensive insights into the disease, historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Explore epidemiology trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Warm Autoimmune Hemolytic Anemia Market Report
• On 24…
Biliary Tract Cancer Market Size Expected to Grow Major Growth by 2034, estimate …
DelveInsight's report, "Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034", provides a comprehensive analysis of biliary tract cancer, including historical trends, epidemiological projections, and market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report evaluates current treatment practices, pipeline therapies, and the market share of existing and emerging interventions. It presents the current and forecasted market size for biliary tract…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
